Results 171 to 180 of about 1,989 (180)

ICER posts on muscular dystrophy, Zolgensma

PharmacoEconomics & Outcomes News, 2019
openaire   +1 more source

Onasemnogene abeparvovec (Zolgensma)

2023
openaire   +1 more source

Curing at a Cost: The Zolgensma Revolution

Medicon Medical Sciences
openaire   +1 more source

Note: Zolgensma data manipulation.

The Medical letter on drugs and therapeutics, 2019
openaire   +1 more source

Zolgensma - rewolucja w leczeniu rdzeniowego zaniku mięśni (SMA) typu I

2021
Jabłońska, Iwona, Bączyk, Joanna, Słota, Jacek, Goławski, Marcin, Machelski, Grzegorz   +4 more
openaire  

Real-World Safety Data of the Orphan Drug Onasemnogene Abeparvovec (Zolgensma®) for the SMA Rare Disease: A Pharmacovigilance Study Based on the EMA Adverse Event Reporting System

Pharmaceuticals
Rosanna Ruggiero, Nunzia Balzano, Maria Maddalena Nicoletti   +2 more
exaly  

Comparing the effectiveness of gene therapies for pediatric spinal muscular atrophy: Zolgensma, spinraza, and risdiplam

Journal of the Neurological Sciences
Jaimin Rathod, Maneet Kaur, Komati Sathwika, Tejsharani Beeram, Zeel Patel, Srijamya Na   +5 more
openaire   +1 more source

Zolgensma - one-time gene therapy for spinal muscular atrophy.

The Medical letter on drugs and therapeutics, 2019
openaire   +1 more source

Health ministers condemn Novartis lottery for Zolgensma, the world’s most expensive drug

BMJ, The
exaly  

Zolgensma e Atrofia Muscular Espinhal: evidências, incertezas e impacto orçamentário

Juliana Alvares
exaly